SBI Life Insurance increased its stake in IPCA Laboratories Limited from 3.58% to 3.69% by purchasing 288,920 shares. The shares were valued at approximately ₹55.48 Cr based on a share price of ₹1920.40.
A pharmaceutical manufacturer and marketer, Ipca Labs produces a wide range of medicines across therapeutic areas including antimalarials, anti-infectives, gastrointestinal treatments, and gynecological formulations. The company operates manufacturing facilities across India and exports its products to international markets. Its distinctive strength lies in its expertise in complex drug formulations, established distribution networks across Indian states, and a focus on affordable healthcare solutions for domestic and global markets.
Joint venture between State Bank of India and BNP Paribas Cardif. Manages over Rs 4.7 lakh crore in total AUM with the flagship SBI Life Equity Fund alone holding over Rs 77,000 crore. One of India's largest private life insurers by AUM, with a multi-cap equity book deployed across ULIP and participating funds.